It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The epicardial administration of therapeutics via the pericardial sac offers an attractive route, since it is minimally invasive and carries no risks of coronary embolization. The aim of this study was to assess viability, safety and effectiveness of cardiosphere-derived cells (CDCs), their extracellular vesicles (EVs) or placebo administered via a mini-thoracotomy 72 h after experimental infarction in swine. The epicardial administration was completed successfully in all cases in a surgery time (knife-to-skin) below 30 min. No significant differences between groups were found in cardiac function parameters evaluated using magnetic resonance imaging before therapy and at the end of the study, despite a trend towards improved function in CDC-treated animals. Moreover, infarct size at 10 weeks was smaller in treated animals, albeit not significantly. Arrhythmia inducibility did not differ between groups. Pathological examination showed no differences, nor were there any pericardial adhesions evidenced in any case 10 weeks after surgery. These results show that the epicardial delivery of CDCs or their EVs is safe and technically easy 3 days after experimental myocardial infarction in swine, but it does not appear to have any beneficial effect on cardiac function. Our results do not support clinical translation of these therapies as implemented in this work.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Fundación Centro de Cirugía de Mínima Invasión Jesús Usón, Cáceres, Spain (GRID:grid.419856.7) (ISNI:0000 0001 1849 4430); Instituto de Salud Carlos III, CIBERCV, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
2 Fundación Centro de Cirugía de Mínima Invasión Jesús Usón, Cáceres, Spain (GRID:grid.419856.7) (ISNI:0000 0001 1849 4430)
3 Instituto de Salud Carlos III, CIBERCV, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427); Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, ICREC Research Group (Insuficiència Cardíaca i REgeneració Cardíaca), Badalona, Spain (GRID:grid.429186.0)
4 Fundación Centro de Cirugía de Mínima Invasión Jesús Usón, Cáceres, Spain (GRID:grid.419856.7) (ISNI:0000 0001 1849 4430); Instituto de Salud Carlos III, CIBERCV, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427); University of Extremadura, Immunology Unit, Cáceres, Spain (GRID:grid.8393.1) (ISNI:0000000119412521); University of Extremadura, Institute of Molecular Pathology Biomarkers, Cáceres, Spain (GRID:grid.8393.1) (ISNI:0000000119412521)